Jyong Biotech Ltd. Ordinary Shares (MENS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has a cash flow conversion efficiency ratio of 0.025x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-913.00K) by net assets ($-36.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MENS market cap overview for the company's overall valuation and market capitalisation.
Jyong Biotech Ltd. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jyong Biotech Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their cash flow conversion efficiency. See MENS operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Valens
NYSE:VLN
|
-0.043x |
|
Dong Hai JSC of Bentre
VN:DHC
|
0.005x |
|
Sparebanken Ost
OL:SPOG
|
0.022x |
|
Nusantara Pelabuhan Handal Tbk PT
JK:PORT
|
0.114x |
|
Huons Global Co. Ltd
KQ:084110
|
0.020x |
|
Solocal Group SA
PA:LOCAL
|
-0.613x |
|
HansBiomed Corporation
KQ:042520
|
0.036x |
|
Ecomate Holdings Bhd
KLSE:0239
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Jyong Biotech Ltd. Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2025. View Jyong Biotech Ltd. Ordinary Shares stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-24.91 Million | $-3.04 Million | 0.122x | +23.04% |
| 2024-12-31 | $-36.52 Million | $-3.62 Million | 0.099x | +30.00% |
| 2023-12-31 | $-34.07 Million | $-2.60 Million | 0.076x | -23.87% |
| 2022-12-31 | $-29.63 Million | $-2.97 Million | 0.100x | +17.88% |
| 2021-12-31 | $-23.32 Million | $-1.98 Million | 0.085x | +50.27% |
| 2020-12-31 | $-19.20 Million | $-1.09 Million | 0.057x | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for t… Read more